PE Firm · Capital Allocator

Vivo Capital

Medium
Headquarters not yet mapped · Website
Last verified
9/19/2026

Firm Overview

94
Portfolio tracked
0
Sectors
0
Regions
9/19/2026
Last verified

Health-care focused investment firm.

Leadership

Frank Kung
Founding Managing Partner
Frank Kung is a Founding Managing Partner of Vivo Capital and has over 30 years of experience in the healthcare industry.
Albert Cha
Managing Partner
Albert Cha joined Vivo Capital in 2000 and focuses on investments in the biopharmaceutical and medical device sectors.
Edgar Engleman
Founding Member
Edgar Engleman is a Founding Member of Vivo Capital and a Professor of Pathology and Medicine at Stanford University School of Medicine.
Chen Yu
Managing Partner
Chen Yu focuses on investment opportunities in the biopharmaceutical and medical device sectors.
Shan Fu
Managing Partner, CEO of Greater China
Shan Fu is a Managing Partner and CEO of Greater China for Vivo Capital.
Hongbo Lu
Managing Partner
Hongbo Lu focuses on private and public investments in the healthcare sector.
Jack Nielsen
Managing Partner
Jack Nielsen joined Vivo Capital in 2017 and focuses on investments in the healthcare sector.
Gaurav Aggarwal
Managing Partner
Gaurav Aggarwal focuses on investments in the biopharmaceutical and medical device sectors.
Michael Chang
Managing Partner
Michael Chang is a Managing Partner and focused on the firm's efforts in Asia.
Kevin Zuo
Managing Director
Kevin Zuo focuses on private equity investments in the healthcare industry.
David Ma
Managing Director
David Ma focuses on growth-stage and buyout investments in the healthcare industry.
Joe Siletto
Managing Director
Joe Siletto focuses on medical device and biopharmaceutical investments.
Nathaniel Zaba
Managing Director
Nathaniel Zaba focuses on biopharmaceutical and medical device investments.
Luke Li
Managing Director
Luke Li focuses on biopharmaceutical and life science tool investments.
Stephan D. Thalen
Managing Director
Stephan D. Thalen focuses on healthcare services and medical technology investments.
Justin P. Klein
Managing Director
Justin P. Klein focuses on medical device and biopharmaceutical investments.

Portfolio Companies

CompanySectorStatusWebsite
Aadi BioscienceCurrentVisit ↗
Ablaze PharmaceuticalsCurrent
Achieve Life SciencesCurrentVisit ↗
ADARx PhamaceuticalsCurrentVisit ↗
Adaxion TherapeuticsCurrentVisit ↗
AerobiotixCurrentVisit ↗
Agno PharmaCurrentVisit ↗
Ajax Therapeutics Inc.CurrentVisit ↗
AkiraBioCurrentVisit ↗
Alto NeuroscienceCurrentVisit ↗
Ascendis PharmaCurrentVisit ↗
Aslan PharmaceuticalsCurrent
Avadel PharmaceuticalsCurrentVisit ↗
Avistone PharmaceuticalsCurrentVisit ↗
BioDlinkCurrentVisit ↗
Bisirna TherapeuticsCurrent
BlossomHill TherapeuticsCurrentVisit ↗
Bolt BiotherapeuticsCurrentVisit ↗
BonraybioCurrentVisit ↗
Bonum TherapeuticsCurrentVisit ↗
CaidyaCurrentVisit ↗
Cidara TherapeuticsCurrentVisit ↗
Clasp TherapeuticsCurrentVisit ↗
Compass PathwaysCurrentVisit ↗
Compass TherapeuticsCurrentVisit ↗
Createrna Science and TechnologyCurrentVisit ↗
Dominique DutscherCurrentVisit ↗
EpibiologicsCurrentVisit ↗
Esco AsterCurrentVisit ↗
Esco Lifesciences GroupCurrentVisit ↗
Evaheart Medical DeviceCurrentVisit ↗
Fortis TherapeuticsCurrentVisit ↗
GenetronCurrentVisit ↗
HanchorBioCurrentVisit ↗
HCMed InnovationsCurrentVisit ↗
HistowizCurrentVisit ↗
Immune-Onc TherapeuticsCurrentVisit ↗
ImmunEdgeCurrent
InspirnaCurrentVisit ↗
Instil BioCurrentVisit ↗
IO BiotechCurrentVisit ↗
IVERIC BioCurrentVisit ↗
Kinaset TherapeuticsCurrentVisit ↗
Kira PharmaceuticalsCurrentVisit ↗
Lepu BiopharmCurrentVisit ↗
Lepu Scientech Medical TechnologyCurrentVisit ↗
MaculogixCurrent
Magnolia Medical TechnologiesCurrentVisit ↗
Mereo BioPharma GroupCurrentVisit ↗
MetacrineCurrentVisit ↗
Minerva NeurosciencesCurrentVisit ↗
NeocisCurrentVisit ↗
NeurogastrxCurrentVisit ↗
New Frontier CorporationCurrentVisit ↗
Oricell TherapeuticsCurrentVisit ↗
Ossium HealthCurrentVisit ↗
Outrigger TherapeuticsCurrent
Pasithea TherapeuticsCurrentVisit ↗
Precision BioSciencesCurrentVisit ↗
ProviviCurrentVisit ↗
PulmocideCurrentVisit ↗
RareStone GroupCurrentVisit ↗
RayzebioCurrentVisit ↗
RemeGenCurrentVisit ↗
Rgenta TherapeuticsCurrentVisit ↗
RiboX TherapeuticsCurrentVisit ↗
Ronovo SurgicalCurrentVisit ↗
Sanegene BioCurrentVisit ↗
Satsuma PharmaceuticalsCurrentVisit ↗
Scientia VascularCurrentVisit ↗
Sera PrognosticsCurrentVisit ↗
Seran BioscienceCurrentVisit ↗
Serapha BioCurrentVisit ↗
Sierra OncologyCurrentVisit ↗
Silence TherapeuticsCurrentVisit ↗
Sinovac BiotechCurrentVisit ↗
Sinovac Life & SciencesCurrentVisit ↗
SonoTheraCurrentVisit ↗
Suzhou Omini PharmaeuticalCurrentVisit ↗
Tarsus PharmaceuticalsCurrentVisit ↗
Tebra TechnologiesCurrentVisit ↗
Tenax TherapeuticsCurrentVisit ↗
Terns PharmaceuticalsCurrentVisit ↗
Theranica Bio-ElectronicsCurrentVisit ↗
Tourmaline BioCurrentVisit ↗
Tranquis TherapeuticsCurrentVisit ↗
Vellum BiotechnologyCurrent
Verona PharmaCurrentVisit ↗
Visen PharmaceuticalsCurrentVisit ↗
Visirna TherapeuticsCurrentVisit ↗
Wanmei InteractiveCurrent
WuXi PharmaTechCurrentVisit ↗
Zai LabCurrentVisit ↗
Zenas BiopharmaCurrentVisit ↗

Source: https://vivocapital.com/portfolio

Portfolio Web Readiness

Not yet assessed

The assessment covers whether AI crawlers and search engines can reach and parse the public site, page performance, transport and security hygiene, and discoverability. 86 portfolio companies have a website on record.

Observational measurements of these companies' public websites only. Not a rating of the companies, their performance, their management, or their investment merit. Not investment advice. Request a correction or removal via Submit Update.

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Vivo Capital and does not provide investment advice.

More PE firms

Browse the full PE firms directory.